We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Trends in relative survival of Diffuse large B‐cell lymphoma in Sweden in the era of targeted and cellular therapies.
- Authors
Smedby, K. Ekström; Antonilli, S.; Enblad, G.; Sonnevi, K.; Wahlin, B. E.; Andersson, P.; Jerkeman, M.; Eloranta, S.
- Abstract
We speculate that the higher survival rate among young high-risk patients may be driven by the introduction of CAR-T in the last few years, whereas the more general and successive improvement among older patients could be due to intensified treatment schemes in the primary as well as relapsed settings. B Introduction: b Most patients diagnosed with diffuse large B-cell lymphoma (DLBCL) are cured with primary immunochemotherapy, but about one in four experience relapsed/refractory (R/R) disease with worsened outcome. In young high-risk patients, the 2-year RS increased from 71% among patients diagnosed 2007-2009, to 83% among patients diagnosed 2019-2021 ( I p i SB overall sb < 0.001).
- Subjects
SWEDEN; DIFFUSE large B-cell lymphomas; CELLULAR therapy; CD19 antigen
- Publication
Hematological Oncology, 2023, Vol 41, p429
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_316